Business Wire

XPeng to Launch Flagship G9 SUV on September 21, 2022

Share

XPeng Inc. (“XPeng” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, is to launch its fourth production model, the flagship G9 SUV, on September 21, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220916005596/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

XPENG G9 FLAGSHIP SUV (Photo: Business Wire)

The G9’s launch event will be broadcast at 07:00 p.m. Beijing time (GMT+8, or 07:00 a.m. US Eastern Time) on Wednesday, September 21, 2022, via the following channels:

English language version:
XPENG OFFICIAL WEBSITE ENGLISH
XPENG OFFICIAL FACEBOOK
XPENG OFFICIAL TWITTER

Chinese language version:
XPENG OFFICIAL WEBSITE CHINESE

About XPeng Inc.

XPeng is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPeng is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Silicon Valley, San Diego and Amsterdam. The Company’s Smart EVs are mainly manufactured at its plant in Zhaoqing, Guangdong province. For more information, please visit https://heyxpeng.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Statements that are not historical facts, including statements about XPeng’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPeng’s goals and strategies; XPeng’s expansion plans; XPeng’s future business development, financial condition and results of operations; the trends in, and size of, China’s EV market; XPeng’s expectations regarding demand for, and market acceptance of, its products and services; XPeng’s expectations regarding its relationships with customers, contract manufacturers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPeng’s filings with the SEC. All information provided in this press release is as of the date of this press release, and XPeng does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Investor Enquiries:
IR Department
XPeng Inc.
Email: ir@xiaopeng.com

Jenny Cai
The Piacente Group
Tel: +1 212 481 2050 / +86 10 6508 0677
Email: xpeng@tpg-ir.com

For Media Enquiries:
PR Department
XPeng Inc.
Email: pr@xiaopeng.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results2.5.2024 13:05:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced results for the fiscal first quarter ended March 31, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502994935/en/ Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results (Graphic: Business Wire) Select First Quarter 2024 Financial Highlights Revenue was $106.7 million for the 2024 first quarter, an increase of 1.2% compared to $105.5 million for the same period last year. U.S. revenue was $53.8 million for the 2024 first quarter, an increase of 0.7% compared to $53.4 million for the same period last year. International revenue was $52.9 million for the 2024 first quarter, an increase of 1.6% compared to $52.1 million for the same period last year. Annuali

Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer2.5.2024 13:00:00 CEST | Press release

Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis. Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer. “Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we of

Lifezone Metals to Provide its Q1 2024 Operational Update and Financial Summary on Monday, May 13, 20242.5.2024 12:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) will release its operational update and unaudited financial summary for the first quarter of 2024 before market open on Monday, May 13, 2024. The company invites shareholders, investors, and members of the media to join the executive team for a virtual presentation and discussion of the Q1 summary and outlook. The presentation will be followed by a Q&A session where participants can engage directly with Lifezone’s senior management. Event details: Date: Monday, May 13, 2024. Time: 10:00 AM Eastern Time. Location: Virtual (please click the webcast registration link). The presentation slides will be available on Lifezone’s website on the day of the release. The webcast will be archived and accessible for replay for a limited time after the event. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Metals (NYSE: LZM), our mission is to provide cleaner and more responsible metals productio

Florin Filote joins ThredUp as General Manager of Europe2.5.2024 12:00:00 CEST | Press release

ThredUp (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, today announced the appointment of Florin Filote as the company’s General Manager of Europe. With nearly two decades of experience in retail and ecommerce with an emphasis on building and scaling marketplace businesses, Filote will oversee the company’s European business operations, which currently span nine countries in Central and Eastern Europe. He succeeds Dan DeMeyere, who has been with ThredUp since 2010 and most recently ran the company’s international business for two years. DeMeyere is transitioning back to the U.S. business to scale technology and artificial intelligence innovation as Chief Product and Technology Officer. Filote and DeMeyere will both report to ThredUp CEO and Cofounder James Reinhart. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502300242/en/ Florin Filote, General Manager of Eu

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma2.5.2024 10:23:00 CEST | Press release

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT (SLIT-liquid) on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe. The publication is available online (https://doi.org/10.1016/j.lanepe.2024.100915) and will be available in print at a later date. This retrospective longitudinal pharmaco-epidemiological real-world study, which evaluated data over a 9-year period, included over 440,000 patients: more than 110,000 patients with allergic rhinitis, with or without asthma, treated with Stallergenes Greer SLIT-liquid and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis, with or without asthma, treated with symptomatic drugs only. The primary objective of the study was the evaluation of the real-world impact of Stallergene

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye